NEW BRUNSWICK, N.J. – Johnson & Johnson had $100 million in sales from the COVID-19 vaccine that was put on hold due to reports of rare blood clots last week.
The company on Tuesday reported first-quarter net income of $6.2 billion, or $2.32 per share. Excluding one-time events, the company had per-share earnings of $2.59, far exceeding Wall Street projections of $2.31, according to a survey of analysts by Zacks Investment Research.
Revenue was $22.32 billion, also surpassing expectations. The world’s biggest maker of health care products expects full-year earnings in the range of $9.42 to $9.57 per share, with revenue in the range of $90.6 billion to $91.6 billion.